ecancer

Current treatment options in mRCC

Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA

23 Sep 2014

Additional treatment options impact first-line treatment of mRCC: No

Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France

23 Sep 2014

Additional treatment options impact first-line treatment of mRCC: Yes

Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

23 Sep 2014

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

23 Sep 2014

From clinical trial to clinical practice: Evidence from the real world

Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain

23 Sep 2014

What have we learned? Expert perspectives

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

23 Sep 2014

ecancermedicalscience editor's choice for September 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

18 Sep 2014

Global prostate cancer disparities and the parts both genetic and behavioural factors play

Dr Folakemi Odedina - College of Pharmacy, University of Florida, Gainesville, USA

28 Aug 2014

Networking and collaborating across borders in sub-Saharan Africa

Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA

26 Jun 2014

Personalised cancer medicine using the human protein atlas and affibodies

Prof Mathias Uhlén - Royal Institute of Technology (KTH), Stockholm, Sweden

26 Jun 2014

ecancermedicalscience editor's choice for June 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

24 Jun 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA

2 Jun 2014

More from ecancer